[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100458180":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":45,"collaborators":47,"id":53,"slug":10,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":10,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Montefiore Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Study group",null,"Patients with physician-diagnosed CRSwNP, with or without comorbid asthma that meet indication criteria for FDA-approved use of Dupilumab.",[13],"Biological: Dupilumab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"BIOLOGICAL","Dupilumab","Standard of care treatment with dupilumab",[9],[21],{"name":22,"affiliation":5,"role":23},"Golda Hudes, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","866-633-8255","ghudes@montefiore.org",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","The Bronx","New York","10461","United States",{"type":37,"coordinates":38},"Point",[39,40],-73.86641,40.84985,{"lat":40,"lon":39},[43,44],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":22,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[48,51],{"name":49,"class":50},"Regeneron Pharmaceuticals","INDUSTRY",{"name":52,"class":6},"Mayo Clinic","100458180",false,"NCT05246267","Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis","Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)","Inclusion Criteria:\n\n* Patients with physician-diagnosed CRSwNP, with or without comorbid asthma that meet indication criteria for FDA-approved use of Dupilumab.\n* Patients aged 18 years and older.\n* Patient willing to provide consent to be a participant in the study.\n* Patients with insurance that allows Dupilumab coverage or Dupilumab coverage obtained through \"Dupixent MyWay Program\"\n\nExclusion Criteria:\n\n* Age under 18\n* Suspected or diagnosed allergic fungal rhinosinusitis.\n* Suspected or diagnosed cystic fibrosis.\n* Dupilumab coverage denied through insurance or \"Dupixent MyWay Program\"\n* Patients who required a steroid taper in the preceding 30 days. However, patients on chronic steroids less or equal to 20 mg of prednisone daily, are eligible.\n* Patients who were on a different biologic medication in the preceding 3 months.\n* Patients with a diagnosis of EGPA\u002FChurg-Strauss Syndrome\n* Pregnant patients\n* Patients with inverted papilloma growth","ALL","18 Years","99 Years",{"count":63,"type":64},60,"ESTIMATED","OBSERVATIONAL","The central hypothesis of this study is that the addition of dupilumab treatment onto standard-of-care intranasal corticosteroids will improve patient-reported measures of disease activity and sense of smell in a cohort of mostly ethnical and racial minority patients with CRSwNP",[68],"Chronic Rhinosinusitis With Nasal Polyps",[70,71],"CRSwNP","dupilumab","2026-01-20",{"date":74,"type":75},"2026-01-22","ACTUAL",{"date":77,"type":75},"2022-02-15",{"date":79,"type":64},"2026-06",{"name":5,"class":6},1]